InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.570 -0.05 (-8.06%)+
Announcement
Release
26 May 2026 8:51AM
Price at Release
$0.620
Full Release
download
Summary
The FY26 Full Year Results Presentation for Aroa Biosurgery Limited focuses on financial performance, strategic growth pillars, and operational strategies. The company achieved a total revenue of NZ$103.9 million, marking a 23% increase from the previous year, with a robust product gross margin of 85.5%. Aroa's Myriad product line showed significant growth, driving a 54% sales increase. The company also maintained a strong cash position with NZ$27 million on hand and reported being debt-free. The strategic focus includes leveraging the Myriad, Symphony, and OviTex platforms to expand in markets such as complex wounds and soft tissue reconstruction. For FY27, Aroa plans to continue investing in sales capabilities to accelerate growth, particularly in the U.S. direct sales market, while aiming for 13-23% revenue growth.
Key Points
  • Total revenue for FY26 was NZ$103.9 million, a 23% increase from FY25.
  • Product gross margin remained high at 85.5%.
  • Myriad product line sales grew by 54%, the highest in the portfolio.
  • Aroa remains debt-free with NZ$27 million cash on hand.
  • Strategic growth focused on Myriad, Symphony, and OviTex products.
  • FY27 guidance includes 13-23% revenue growth with continued investment in sales capacity.
  • The company aims to leverage existing evidence and clinical studies to drive market expansion.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.